Current EAU guidelines recommend to perform PSMA-labeled PET/CT for imaging PCa with biochemical recurrence if PSA level is greater than 0.2 ng/mL and if results will influence subsequent treatment decisions; whilst [18F]Fluciclovine or Choline-radiolabeled PET/CT are recommended in the case of PSMA-labeled PET/CT is not available and PSA is greater than 1 ng/mL [1]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.